Nimesulide incident triggers Canchi drug "adverse reaction"

By the main products Rui Zhi Qing "nimesulide children drug adverse Reaction" incident, Canchi Pharmaceutical Industry (300086) yesterday fell 8.49%, trading data showed that day transactions of 570 million yuan, the agency fled the obvious signs, only 5 institutions dedicated seats sold more than 200 million yuan.　　Canchi Pharmaceutical Vice general manager and Dong-Li Youquan told the Securities Times reporter, the safety of nimesulide drugs has been identified by the state Drug Administration, Canchi pharmaceutical industry to multinational companies Johnson Pharmaceutical unfair Competition report is still in Hainan trade and Industry Bureau to accept. Yesterday, in the main web site of the Canchi pharmaceutical stocks, investors on the Canchi pharmaceutical industry in the Seretide incident in the United States expressed dissatisfaction. The reporter learned that the nimesulide incident first appeared in the "2010 Child Safety Medication International Forum", the forum said, in November last year, Beijing Children's Drug Safety International Forum, a pediatrician pointed out that there have been nimesulide injury to the central nervous and liver cases, nimesulide as a child fever medication need to be used carefully,　　The Forum has recently been a number of media attention, some media even directly to Canchi medicine Rui Zhi Qing known as the "Kill Fever Medicine."　　Canchi pharmaceutical Industry yesterday's clarification announcement said, the report of the adverse reaction of nimesulide is seriously inconsistent with the facts, according to the national Adverse Reaction Monitoring Center issued the "ADR Information Bulletin", in the past decade in our country has no nimesulide-related adverse reaction of the information bulletin, and Rui Zhi Qing listed in the nine years have never had a serious adverse reaction. Li Youquan said, domestic nimesulide production enterprises have 33, alone Canchi pharmaceutical industry Rui Zhi Qing proposed to do attack target, appears to have ulterior motives.　　He said that Canchi Medicine has reported to the Hainan Province Trade and Industry Bureau of the multinational company Johnson pharmaceutical companies in the incident malicious attack against rivals of the bad competition, the corporation also reserves the right to further access to the law.　　And until the reporter press time, Johnson China did not respond to this. The state Food and Drug Administration, which was interviewed yesterday, said the drug would not be off the shelf because the product was approved by the National Drug Administration. The person said that the state Food and Drug Administration has been concerned about the Nimesulide incident, has organized the National ADR Monitoring Center experts on the safety of nimesulide further argument, will soon be published results.　　He also said that the state Food and Drug Administration in 2008 had a new review of the specification of Nimesulide, the ADR Monitoring Center is still closely monitoring the use of foreign and domestic provinces and cities. It is reported that China's current sale of children's antipyretic and analgesic drugs are mainly divided into three categories, in addition to the Canchi pharmaceutical products Rui Zhi Qing as the representative of the Nimesulide series, as well as the Johnson Merrill Lynch representative of the series of ibuprofen and the amino phenol series.　　Rui Zhi Qing as a child antipyretic and analgesic drugs, rising rapidly in recent years, the 2009 market share of 18.2%, Liquan Securities analyst in the forecast this year Rui Zhi Qing's market share is still higher than Merrill Lynch. A number of medical analysts declined to comment on the impact of the Nimesulide incident on the Canchi pharmaceutical industry, and the northeastern Securities and pharmaceutical analyst was only willing to reviewCanchi Pharmaceutical Sales Model. According to the analyst, Canchi Pharmaceuticals is the pioneer of the third terminal sales of domestic pharmaceutical enterprises, and has been involved in the medical retail terminals including rural and rural-urban integration since 2002, with more than 70% of sales currently from the third terminal. It is reported that 2009, Rui Zhi Qing single products accounted for Canchi pharmaceutical business profit of 89%, the company launched last year after the release of tannic acid protein yeast powder and Lactobacillus granules two new products, although rapid growth, but because the base is low, it is still difficult to provoke income beam.